Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -100 million and -75 million yuan[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -450 million and -360 million yuan for 2025[3]. - In the same period last year, the net profit attributable to shareholders was -538.91 million yuan, and the net profit after deducting non-recurring gains and losses was -404.67 million yuan[5]. Operational Challenges - The company is currently undergoing bankruptcy reorganization, which has impacted operational activities and led to losses[6]. - Production line technical upgrades have resulted in insufficient capacity release and high fixed costs, contributing to the expected losses[6]. - The company plans to recognize impairment provisions for long-term assets and inventory due to the high costs of certain products and idle equipment[6]. Forecast and Investment Risks - The performance forecast has not been audited by registered accountants, and the company has not identified significant uncertainties affecting the accuracy of the forecast[7]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change in the official annual report[8].
宁科生物(600165) - 2025 Q4 - 年度业绩预告